Gynaecology News and Research

RSS

Covidien launches SILS stitch suturing device for advanced laparoscopic surgery

Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the worldwide launch of the SILS™ Stitch articulating suturing device for advanced laparoscopic surgery, including SILS single-incision procedures. The SILS Stitch instrument expands the Company’s SILS product line, as well as its endoscopic suturing portfolio, which includes today’s leading automated endosuturing product, the Endo Stitch™ instrument and reloads.

18 May 2010

Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA

Ferring Pharmaceuticals today announced an agreement that will expand its Women's Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical's LYSTEDA™ (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB).

10 May 2010

Homeopathy – Is it a safer and effective alternative?

Studies have shown that nearly 45% Britons rely on Homeopathy, a branch of medicine that has been doubted by many and loved by an equal number.

20 Apr 2010

Valedictory Symposium to celebrate Professor David Taylor's contribution to Obstetrics and Gynaecology

Medical experts from across the UK are gathering at the University of Leicester on Friday 23rd April in a Valedictory Symposium to celebrate the work of Professor David Taylor.

19 Apr 2010

Elective single embryo transfer for Canadian women under 35 most efficacious and cost-effective option

Many Canadian couples battling infertility turn to in vitro fertilization (IVF) to have a child. In Canada, IVF is not publicly funded, making the decision on the number of embryos to be transferred more complicated than in many European countries which link funding to elective single embryo transfer (eSET).

16 Apr 2010

NPCs as effective as doctors in performing Caesarean sections

Every year, some 7.5 million mothers and new-borns die during pregnancy or childbirth, almost all of whom are in low and middle-income countries. One reason for this is the lack of trained medical staff, particularly doctors. A doctoral thesis from Karolinska Institutet now shows that a solution could be the training of nurses in caesarean sections and other life-saving surgery.

3 Apr 2010

Study evaluates OCP treatment to prevent endometrioma recurrence

Ovarian endometriomas, better known as ovarian 'chocolate' cysts for the brown liquid they contain, can be easily removed by surgery. However, recurrence is common, which can cause ongoing pain and complications. A study evaluated for Faculty of 1000 suggests a simple and effective remedy - the oral contraceptive pill.

31 Mar 2010

Pregnant breast cancer patients can receive chemotherapy without endangering baby health

Women who discover they have breast cancer while they are pregnant can be treated with chemotherapy without endangering the health of their unborn baby, according to research to be presented at the seventh European Breast Cancer Conference (EBCC7) in Barcelona today (Friday).

26 Mar 2010

HPV test could help predict risk of cervical cancer, but more research needed

Testing for the human papillomavirus (HPV) - the major cause of cervical cancer - may not help to identify women who are at risk of the disease, a new UK study suggests.

24 Mar 2010

TomTec Imaging Systems to present radiology and software solutions at the upcoming ECR

Customers and business partners are invited to visit TomTec’s booth at the upcoming ECR in Vienna.

3 Mar 2010

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Obecure Ltd (http://www.obecure.com)., a subsidiary of Bio-Light Israeli Life Science Investments Ltd., announced today the execution of a licensing and clinical supply agreement with Farmaceutici Formenti SPA, the Italian Subsidiary of the Grunenthal Group.

17 Feb 2010

Big Ow awareness campaign

When it comes to symptoms of menopause like hot flashes, weight gain or trouble sleeping, chances are most women wouldn't hesitate to speak to their doctor. But there is another common - and equally distressing - effect of menopause that many women just keep to themselves. The Big Ow, also known as vaginal atrophy, will affect as many as two million Canadian women in the next 10 years - but most are too shy or embarrassed to talk about it, even with their doctor.

8 Feb 2010

Submissions invited for 2010 SOGC/CFWH Journalism Awards for Excellence in Women's Health Reporting

The Society of Obstetricians and Gynaecologists of Canada (SOGC), in collaboration with the Canadian Foundation for Women's Health (CFWH), is calling for submissions for the 2010 SOGC/CFWH Journalism Awards for Excellence in Women's Health Reporting.

29 Jan 2010

Preliminary results from Nektar Therapeutics' NKTR-102 Phase 2 study in platinum-resistant ovarian cancer

Nektar Therapeutics today announced preliminary results from the first stage of a two-stage Phase 2 clinical study evaluating NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients enrolled with platinum-resistant disease were evaluable for the primary endpoint of overall response rate using Gynecologic Cancer InterGroup (GCIG) criteria, i.e., a combination of response by tumor imaging

12 Jan 2010

TomTec introduces Image-Arena multimodality platform

TomTec the leading innovator for cardiac imaging presents its next generation Image-Arena™ multimodality platform for Image Analysis, Review and Data Management at the EuroEcho in Madrid.

7 Dec 2009

TomTec Imaging Systems to present new technology for radiologic ultrasound at upcoming RSNA conference

TomTec Imaging Systems, the leading innovator for cardiac image analysis and image management will present its new technology for radiologic ultrasound at the upcoming RSNA conference in Chicago.

26 Nov 2009

TomTec Imaging Systems showcases its new cardiac multimodality workstation at the RSNA

TomTec, the leading innovator for cardiac image analysis and image management, shows its new cardiac multimodality workstation at the RSNA in Chicago!

25 Nov 2009

Positive efficacy data from Phase 2 study of AEZS-108 announced

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with advanced or recurrent endometrial cancer.

25 Nov 2009

Positive data from Æterna Zentaris' Phase 2 targeted cytotoxic peptide conjugate study

Æterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with advanced or recurrent endometrial cancer.

24 Nov 2009

New study reveals certain prescription drugs can be harmful to fetus

More than six percent of expectant mothers in Quebec consume prescription drugs that are known to be harmful to their fetuses, according to a Universit- de Montr-al investigation published in the British Journal of Obstetrics and Gynaecology

18 Nov 2009